May 28, 2013
Market Report, "Crucell N.V. - Strategic SWOT Analysis Review", published
Crucell N.V. is a biopharmaceutical company. It discovers, develops, manufactures and markets vaccines and antibodies indicated against infectious diseases.
Johnson & Johnson chief Gorsky elected to chairman of the board
Weldon will step down as chairman on Dec. 28 and plans to retire in the first quarter of 2013, the New Brunswick-based company said in a statement today.
Crucell N.V. - SWOT, Strategy and Corporate Finance Report - new company profile report published
The report covers the companys structure, operation, SWOT analysis, product and service offerings, detailed financials, and corporate actions, providing a 360E s view of the company.
Crucell N.V. a " Mergers & Acquisitions (M&A), Partnerships &...
Crucell N.V. A A A' Mergers & Acquisitions , Partnerships & Alliances and Investment Report - new company profile report published 2012-10-22 14:11:50 - Crucell N.V. A A A' Mergers & Acquisitions , Partnerships & Alliances and Investment Report - a new company profile report on companiesandmarkets.com The Company Mergers & Acquisitions , ... (more)
Mucosis B.V. Signs Research and License Option Agreement With Crucell N.V.
Mucosis BV, a clinical-stage Dutch biotechnology company developing innovative mucosal vaccines, today announced that it has signed a Research and License Option Agreement with Crucell Holland B.V. , the Dutch developer of vaccines and antibodies.